Home Newsfeeds Teva Received FDA Approval for Tasimelteon

Teva Received FDA Approval for Tasimelteon

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211601

byCharles Gross

December 13, 2022

1 minute read

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211601

Raymond James Maintains Outperform on Stag Industrial, Lowers Price Target to $36

By Benzinga Newsdesk

October 11, 7:47 AM

Raymond James analyst William Crow maintains Stag Industrial (NYSE:STAG) with a Outperform and lowers the price target from $39 to $36.

STAG

News

Why Getaround (GETR) Shares Are Exploding Higher

By Henry Khederian

May 1, 8:58 AM

Getaround shares are trading higher by 49% to $0.30 during Wednesday's session. The company announced it secured up to $50 million in additional financing.

GETR

IBM Emerges Victorious In $1.6B Legal Battle: Report

By Shivani Kumaresan

May 1, 7:44 AM

IBM secures legal victory, saving $1.6 billion in damages awarded to BMC Software Inc. The U.S. 5th Circuit Court of Appeals rules in favor of IBM, citing lawful acquisition of AT&T's software account. Judges affirm IBM's good faith in the dispute, nullifying one of the largest-ever commercial judgments.

FDL

Franco-Nevada Q2 EPS $1.02 Beats $0.98 Estimate, Sales $352.30M Beat $345.29M Estimate

By Benzinga Newsdesk

August 10, 5:03 PM

Franco-Nevada (NYSE:FNV) reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of $0.98 by 4.08 percent. This is a 6.25 percent increase over earnings of $0.96 per share from the same

FNV

Teva Received FDA Approval for Tasimelteon

Related Posts

Raymond James Maintains Outperform on Stag Industrial, Lowers Price Target to $36

Why Getaround (GETR) Shares Are Exploding Higher

IBM Emerges Victorious In $1.6B Legal Battle: Report

Franco-Nevada Q2 EPS $1.02 Beats $0.98 Estimate, Sales $352.30M Beat $345.29M Estimate